多能干细胞在心脏发育和疾病研究中的应用  

Application of pluripotent stem cells in cardiac development and disease research

作　　者：武玉康[1] 康九红[1] Wu Yukang;Kang Jiuhong(National Stem Cell Translational Resource Center,School of Life Sciences and Technology,Tongji University,Shanghai 200092,China)

机构地区：[1]同济大学生命科学与技术学院国家干细胞转化资源库,上海200092

出　　处：《中华细胞与干细胞杂志（电子版）》2022年第6期378-382,共5页Chinese Journal of Cell and Stem Cell（Electronic Edition）

摘　　要：多能干细胞(PSCs)成功建立标志着再生医学时代的开始。PSCs定向心肌样细胞分化一定程度上重现了体内的心脏发育过程,为研究心脏发育的分子机制提供了平台。此外,PSCs源心肌细胞(PSC-CMs)还能够用于心脏疾病建模、药物心脏毒性检测以及细胞移植治疗等,是基础研究和临床治疗最具潜力的功能性细胞类型。本文着重介绍了PSCs定向心肌细胞分化技术、定向心肌细胞分化在解析心脏发育分子机制方面的应用,以及PSCs源心肌细胞在疾病模型构建、药物的心脏安全性检测和疾病再生医学治疗方面的最新研究进展。The establishment of pluripotent stem cells(PSCs)marked the beginning of regenerative medicine.Cardiomyocyte differentiation of PSCs partially replicates the regulation mode of cardiac development in vivo,so it is believed as an ideal model for studying the molecular mechanisms of cardiac development in vitro.Furthermore,pluripotent stem cell-derived cardiomyocytes(PSC-CMs),as a promising functional cells for basic research and cell therapy,play an immense role in cardiac disease modelling,drug cardiotoxicity testing/drug discovery and cell therapy.Here,we highlight the current strategies of cardiomyocyte differentiation,the role of PSCs differentiation in resolving the molecular mechanisms of cardiac development,and the progress of PSC-CMs in cardiac disease modelling,drug cardiotoxicity testing and cell transplantation therapy.

关 键 词：多能干细胞 心肌细胞 心脏疾病 疾病模型 药物筛选 移植 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]